HYDERABAD: Dr. Reddy's Laboratories has announced the launch of Reditux, a monoclonal antibody (MAb) used in the treatment of Non-Hodgkin's Lymphoma (NHL).
Reditux was unveiled here on Monday in the presence of 100 leading oncologists. The launch was followed by a technical session on the development of the drug.
NHL describes a group of cancers arising from lymphocytes, a type of white blood cell.
It is distinct from Hodgkin lymphoma in its pathologic features, epidemiology, common sites of involvement, clinical behaviour, and treatment.
Talking at the technical session Dr Anji Reddy, Chairman, Dr. Reddy's Laboratories said, "Reditux is yet another example of this commitment. This is a proud moment for the organisation, to know that we have succeeded in developing this very complex molecule which will help in providing an affordable solution to patients."